MRI-guided focused ultrasound for treating Parkinson’s disease with human mesenchymal stem cells
Abstract Parkinson’s disease (PD) is a progressive disorder that affects the nervous system and causes regions of the brain to deteriorate. In this study, we investigated the effects of MR-guided focused ultrasound (MRgFUS) for the delivery of human mesenchymal stem cells (MSCs) on the 6-hydroxydopa...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-85811-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594780193816576 |
|---|---|
| author | Sheng-Kai Wu Chia-Lin Tsai Aisha Mir Kullervo Hynynen |
| author_facet | Sheng-Kai Wu Chia-Lin Tsai Aisha Mir Kullervo Hynynen |
| author_sort | Sheng-Kai Wu |
| collection | DOAJ |
| description | Abstract Parkinson’s disease (PD) is a progressive disorder that affects the nervous system and causes regions of the brain to deteriorate. In this study, we investigated the effects of MR-guided focused ultrasound (MRgFUS) for the delivery of human mesenchymal stem cells (MSCs) on the 6-hydroxydopamine (6-HODA)-induced PD rat model. MRgFUS-induced blood-brain barrier (BBB) permeability modulation was conducted using an acoustic controller with the targets at the striatum (ST) and SN. Human MSCs were injected immediately before sonication. Here, we show that we can deliver human MSCs into Parkinsonian rats through MRgFUS-induced BBB modulation using an acoustic controller. Stem cells were identified in the sonicated brain regions using surface markers, indicating the feasibility of MSC delivery via MRgFUS. MSCs + FUS treatment significantly improved the behavioural outcomes compared with control, FUS alone, and MSCs alone groups (p < 0.05). In the quantification analysis of the TH stain, a significant reservation of dopamine neurons was seen in the MSCs + FUS group as compared with the MSCs group (ST: p = 0.03; SN: p = 0.0005). Mesenchymal stem cell therapy may be a viable treatment option for neurodegenerative diseases such as Parkinson’s. Transcranial MRgFUS serves as an efficacious and safe method for targeted and minimally invasive stem cell homing. |
| format | Article |
| id | doaj-art-94d6e7c838fe42fcbc688e8c8ad59c0e |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-94d6e7c838fe42fcbc688e8c8ad59c0e2025-01-19T12:19:59ZengNature PortfolioScientific Reports2045-23222025-01-0115111110.1038/s41598-025-85811-8MRI-guided focused ultrasound for treating Parkinson’s disease with human mesenchymal stem cellsSheng-Kai Wu0Chia-Lin Tsai1Aisha Mir2Kullervo Hynynen3Physical Sciences Platform, Sunnybrook Research InstitutePhysical Sciences Platform, Sunnybrook Research InstitutePhysical Sciences Platform, Sunnybrook Research InstitutePhysical Sciences Platform, Sunnybrook Research InstituteAbstract Parkinson’s disease (PD) is a progressive disorder that affects the nervous system and causes regions of the brain to deteriorate. In this study, we investigated the effects of MR-guided focused ultrasound (MRgFUS) for the delivery of human mesenchymal stem cells (MSCs) on the 6-hydroxydopamine (6-HODA)-induced PD rat model. MRgFUS-induced blood-brain barrier (BBB) permeability modulation was conducted using an acoustic controller with the targets at the striatum (ST) and SN. Human MSCs were injected immediately before sonication. Here, we show that we can deliver human MSCs into Parkinsonian rats through MRgFUS-induced BBB modulation using an acoustic controller. Stem cells were identified in the sonicated brain regions using surface markers, indicating the feasibility of MSC delivery via MRgFUS. MSCs + FUS treatment significantly improved the behavioural outcomes compared with control, FUS alone, and MSCs alone groups (p < 0.05). In the quantification analysis of the TH stain, a significant reservation of dopamine neurons was seen in the MSCs + FUS group as compared with the MSCs group (ST: p = 0.03; SN: p = 0.0005). Mesenchymal stem cell therapy may be a viable treatment option for neurodegenerative diseases such as Parkinson’s. Transcranial MRgFUS serves as an efficacious and safe method for targeted and minimally invasive stem cell homing.https://doi.org/10.1038/s41598-025-85811-8Mesenchymal stem cellsMR-guided focused ultrasoundParkinson’s disease6-hydroxydopamine |
| spellingShingle | Sheng-Kai Wu Chia-Lin Tsai Aisha Mir Kullervo Hynynen MRI-guided focused ultrasound for treating Parkinson’s disease with human mesenchymal stem cells Scientific Reports Mesenchymal stem cells MR-guided focused ultrasound Parkinson’s disease 6-hydroxydopamine |
| title | MRI-guided focused ultrasound for treating Parkinson’s disease with human mesenchymal stem cells |
| title_full | MRI-guided focused ultrasound for treating Parkinson’s disease with human mesenchymal stem cells |
| title_fullStr | MRI-guided focused ultrasound for treating Parkinson’s disease with human mesenchymal stem cells |
| title_full_unstemmed | MRI-guided focused ultrasound for treating Parkinson’s disease with human mesenchymal stem cells |
| title_short | MRI-guided focused ultrasound for treating Parkinson’s disease with human mesenchymal stem cells |
| title_sort | mri guided focused ultrasound for treating parkinson s disease with human mesenchymal stem cells |
| topic | Mesenchymal stem cells MR-guided focused ultrasound Parkinson’s disease 6-hydroxydopamine |
| url | https://doi.org/10.1038/s41598-025-85811-8 |
| work_keys_str_mv | AT shengkaiwu mriguidedfocusedultrasoundfortreatingparkinsonsdiseasewithhumanmesenchymalstemcells AT chialintsai mriguidedfocusedultrasoundfortreatingparkinsonsdiseasewithhumanmesenchymalstemcells AT aishamir mriguidedfocusedultrasoundfortreatingparkinsonsdiseasewithhumanmesenchymalstemcells AT kullervohynynen mriguidedfocusedultrasoundfortreatingparkinsonsdiseasewithhumanmesenchymalstemcells |